Cardiology – Page 7

Semaglutide for Secondary CVD Prevention: Evaluating the Price of Clinical Success

By MedXY 02/05/2026

A simulation study reveals that while semaglutide significantly reduces cardiovascular events in adults with obesity, its current cost exceeds traditional cost-effectiveness thresholds, requiring an 18% price reduction for broader economic viability.

Cardiology Hematology-Oncology news

Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis

By MedXY 02/05/2026

A prespecified analysis of the AZALEA-TIMI 71 trial demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older patients with atrial fibrillation, potentially offering a safer alternative for high-risk geriatric populations.

Cardiology General Surgery news

Anatomically Directed HGF Gene Therapy Significantly Accelerates Ulcer Healing in Chronic Limb-Threatening Ischemia: Insights from the LEGenD-1 Trial

By MedXY 02/04/2026

The LEGenD-1 trial demonstrates that intramuscular HGF gene therapy (AMG0001) significantly reduces healing time for neuroischemic ulcers in patients with moderate chronic limb-threatening ischemia, offering a potential nonsurgical therapeutic breakthrough for an underserved patient population.

Cardiology Internal Medicine news

Beyond HDL-C: How Macronutrient Shifts Reshape HDL Subspecies to Reduce Coronary Risk

By MedXY 02/04/2026

The OmniHeart trial reveals that replacing dietary carbohydrates with unsaturated fats or protein favorably modifies 15 minor protein-based HDL subspecies, shifting the proteomic profile toward lower coronary heart disease risk, independent of total HDL-C levels.

Cardiology Diabetes & Endocrinology news

GLP-1 Receptor Agonists Significantly Reduce Atrial Fibrillation Recurrence and Mortality Following Catheter Ablation in Obese Patients

By MedXY 02/04/2026

This large-scale real-world analysis reveals that GLP-1 receptor agonist therapy reduces atrial fibrillation recurrence by 18% and lowers all-cause mortality in obese patients following catheter ablation, highlighting a potent upstream strategy for rhythm control.

Cardiology news

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable CAD: The FAME 2 Trial

By MedXY 02/04/2026

The 11-year FAME 2 trial results confirm that FFR-guided PCI significantly improves outcomes for stable CAD patients with functionally significant lesions, primarily by reducing urgent revascularizations, reinforcing the importance of physiological assessment in revascularization decisions.

Cardiology Diabetes & Endocrinology news

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

By MedXY 02/04/2026

This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a critical adjunctive therapy in metabolic-arrhythmic management.

Cardiology news

Bridging the Gap: Why In-Procedure QFR Variability May Explain the FAVOR III Europe Outcomes

By MedXY 02/04/2026

The REPEAT-QFR study reveals modest agreement between in-procedure and core laboratory quantitative flow ratio (QFR) measurements, suggesting that angiographic quality and user adherence significantly impact diagnostic accuracy.

Cardiology news

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable Coronary Artery Disease

By MedXY 02/04/2026

An 11-year follow-up of the FAME 2 trial reveals that FFR-guided PCI significantly outperforms medical therapy alone in patients with hemodynamically significant stenoses, primarily by reducing urgent revascularizations, with a favorable win ratio of 1.25.

Cardiology Diabetes & Endocrinology news

Circadian Heart Rate Fluctuations: A Potent 21-Year Predictor of Mortality in Patients with Diabetes

By MedXY 02/04/2026

A 21-year longitudinal study demonstrates that impaired circadian heart rate fluctuations, measured via 24-hour ambulatory monitoring, significantly predict cardiovascular and all-cause mortality in diabetes, offering a low-cost, accessible tool for identifying high-risk patients.

Cardiology Diabetes & Endocrinology news

Haptoglobin Levels and Phenotype as Determinants of Cardiovascular Risk in Type 2 Diabetes: Insights from the FIELD Sub-study

By MedXY 02/04/2026

This FIELD sub-study reveals that while Haptoglobin 1-1 phenotype combined with low HP levels indicates the lowest CVD risk in Type 2 Diabetes, higher HP levels significantly increase risk, particularly within the HP 1-1 group. Fenofibrate benefits appear independent of HP status.

Cardiology Diabetes & Endocrinology news

Beyond Blood Sugar: Why Insulin Resistance Drives Vagal Dysfunction in Heart Failure

By MedXY 02/04/2026

Evidence from the Myovasc study reveals that insulin resistance and C-peptide levels are independent predictors of impaired cardiac vagal activity in heart failure, suggesting that metabolic health directly influences autonomic regulation beyond simple glycemic control.

Cardiology news

Bridging the Gap: Understanding In-Procedure Variability and Quality Control in the FAVOR III Europe QFR Analysis

By MedXY 02/03/2026

The REPEAT-QFR study reveals a modest 72% diagnostic agreement between bedside and core-lab QFR. The findings underscore that angiographic quality and strict adherence to standard operating procedures are essential for accurate, non-invasive coronary physiology assessment in clinical practice.

Cardiology Diabetes & Endocrinology news

Diminished Circadian Heart Rate Fluctuations: A Potent Predictor of 21-Year Mortality in Patients with Diabetes

By MedXY 02/03/2026

A 21-year longitudinal study reveals that blunted circadian heart rate variability and nocturnal dipping are independent predictors of cardiovascular and all-cause mortality in type 1 and type 2 diabetes, offering a low-cost risk stratification tool via ambulatory monitoring.

Cardiology Diabetes & Endocrinology news

Haptoglobin 1-1 and Low Protein Levels: Identifying the Lowest Cardiovascular Risk in Type 2 Diabetes

By MedXY 02/03/2026

A FIELD sub-study reveals that while higher haptoglobin levels increase cardiovascular risk—particularly in those with the HP 1-1 phenotype—fenofibrate's protective effects remain consistent regardless of haptoglobin status, challenging previous assumptions about phenotype-specific treatment responses.

Cardiology Diabetes & Endocrinology news

Insulin Metabolism as a Primary Driver of Cardiac Autonomic Dysfunction in Heart Failure: Insights from the Myovasc Study

By MedXY 02/03/2026

The Myovasc study demonstrates that insulin resistance and secretion markers, rather than glucose levels alone, are independently associated with impaired cardiac vagal activity in heart failure patients, suggesting a metabolic-autonomic axis that requires targeted clinical attention.

Cardiology Internal Medicine news

Beyond the Clock: How Circadian Rhythm and Life’s Essential 8 Shape Cardiovascular Longevity

By MedXY 02/03/2026

Recent studies from the UK Biobank and Framingham Heart Study reveal that evening chronotypes face higher cardiovascular risks, largely mediated by poor adherence to the Life’s Essential 8 (LE8) health metrics, highlighting the critical role of modifiable behaviors in circadian-related health disparities.

Cardiology Diabetes & Endocrinology news

Type 1 Diabetes Confers Double the Risk of Coronary Stent Failure Compared to Non-Diabetics: A SWEDEHEART Analysis

By MedXY 02/02/2026

A nationwide SWEDEHEART study reveals that while second-generation drug-eluting stents have improved outcomes, patients with Type 1 and Type 2 diabetes remain at significantly higher risk for stent failure, with Type 1 patients facing a more than twofold increased risk.

Cardiology Diabetes & Endocrinology news

Beyond Weight Loss: CagriSema Emerges as a Potent Antihypertensive in Obesity Management

By MedXY 02/02/2026

The REDEFINE 1 trial demonstrates that CagriSema, a semaglutide/cagrilintide combination, significantly reduces blood pressure in adults with overweight or obesity, even among those with resistant hypertension, while facilitating the reduction of concomitant antihypertensive medications.

Cardiology Nephrology news

Dapagliflozin Improves Vascular Stiffness and Cardiorenal Hemodynamics: New Insights from a Randomized Controlled Trial

By MedXY 02/02/2026

A 12-week randomized trial demonstrates that dapagliflozin significantly reduces arterial stiffness and modulates fluid dynamics in patients at cardiovascular risk, regardless of diabetes status, providing a mechanistic basis for its broad cardiorenal protective effects.